60 minutes isn’t going to look into CYDY/Leronlimab because of 1 mTNBC patient who had a “significant” reduction in CTCs and a reduced tumor size. Now, if there are 5 patients with similar results and the FDA grants BTD, well then maybe it’s time to start contacting news agencies.

Nearly every OTC biotech board thinks their drug deserves news attention, but unfortunately, most don’t and never will. In my opinion, Leronlimab is getting there with cancer, with PreP, and with Dr. Sacha’s “cure paper,” but we’re still a little ways off.